FDA Calendar for Keryx Biopharmaceuticals (KERX)

| Register (free)
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Keryx is developing KRX-0401 (perifosine), oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in Phase II clinical development for multiple tumor types.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Zerenex Other UnknownPhase 2
Perifosine Cancer UnknownPhase 3


Events

No future events listed at this time, please check back later.
1 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

KERX

$3.60
0.09 +2.56%
2/3/2012 4:00:00 PM

Sponsors

Other Links